94. 原発性硬化性胆管炎
[臨床試験数:134,薬物数:105(DrugBank:37),標的遺伝子数:18,標的パスウェイ数:131

Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-000204-14-AT
(EUCTR)
13/12/201926/06/2019A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without CirrhosisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor inNon-Cirrhotic Subjects with Primary Sclerosing Cholangitis. Primary Sclerosing Cholangitis
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Cilofexor
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Product Name: Cilofexor
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Gilead Sciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Phase 3United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Australia;Denmark;Germany;Netherlands;Japan;New Zealand;Sweden
2EUCTR2019-000204-14-DK
(EUCTR)
08/11/201908/07/2019A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without CirrhosisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor inNon-Cirrhotic Subjects with Primary Sclerosing Cholangitis. Primary Sclerosing Cholangitis
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Cilofexor
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Product Name: Cilofexor
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Gilead Sciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Phase 3United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Denmark;Australia;Germany;Netherlands;Japan;New Zealand;Sweden
3NCT04060147
(ClinicalTrials.gov)
October 17, 201915/8/2019Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisA Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisPrimary Sclerosing Cholangitis;Compensated CirrhosisDrug: CILOGilead SciencesNULLRecruiting18 Years75 YearsAll20Phase 1United States
4EUCTR2019-000204-14-FI
(EUCTR)
11/09/201924/06/2019A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without CirrhosisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor inNon-Cirrhotic Subjects with Primary Sclerosing Cholangitis. Primary Sclerosing Cholangitis
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Cilofexor
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Product Name: Cilofexor
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Gilead Sciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Phase 3United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Australia;Denmark;Germany;Netherlands;Japan;New Zealand;Sweden
5EUCTR2019-000204-14-ES
(EUCTR)
29/08/201912/09/2019A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without CirrhosisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 inNon-Cirrhotic Subjects with Primary Sclerosing Cholangitis. Primary Sclerosing Cholangitis
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Gilead Sciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Phase 3United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Australia;Denmark;Germany;Netherlands;Japan;New Zealand;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2019-000204-14-GB
(EUCTR)
15/07/201927/06/2019A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without CirrhosisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Cilofexor
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Product Name: Cilofexor
Product Code: GS-9674
INN or Proposed INN: Cilofexor
Other descriptive name: GS-9674
Gilead Sciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Phase 3United States;Finland;Spain;Austria;Israel;Switzerland;United Kingdom;Italy;France;Canada;Belgium;Australia;Denmark;Germany;Netherlands;Japan;New Zealand;Sweden
7NCT03890120
(ClinicalTrials.gov)
March 27, 201925/3/2019Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing CholangitisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing CholangitisPrimary Sclerosing CholangitisDrug: Cilofexor;Drug: PlaceboGilead SciencesNULLRecruiting18 Years75 YearsAll400Phase 3United States;Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New Zealand;Spain;Switzerland;United Kingdom
8NCT02943460
(ClinicalTrials.gov)
November 29, 201613/6/2016Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without CirrhosisA Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Subjects With Primary Sclerosing Cholangitis Without CirrhosisPrimary Sclerosing CholangitisDrug: Cilofexor;Drug: Placebo to match CilofexorGilead SciencesNULLCompleted18 Years70 YearsAll52Phase 2United States;Austria;Canada;United Kingdom
9NCT02808312
(ClinicalTrials.gov)
July 13, 201617/6/2016Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic FunctionA Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic FunctionNonalcoholic Steatohepatitis (NASH);Primary Sclerosing Cholangitis (PSC)Drug: CilofexorGilead SciencesNULLCompleted18 YearsN/AAll57Phase 1United States;New Zealand